Insulin aspart, lispro, or glulisine are recommended in pump-treated type 1 diabetes (T1D). Aspart pharmacokinetics has been studied ([@B1]), but little is known about its reproducibility and associations with anthropometric and clinical factors.

We analyzed retrospectively data collected in 70 pump-treated subjects with T1D, comprising 39 females, 46 young, with mean (SD) BMI 22.7 (4.2) kg/m^2^, A1C 8.1% (1.3) (65.3 \[14.4\] mmol/mol), and total daily insulin 0.8 (0.3) units/kg/day, who were undergoing investigations, with ethical approval, of closed-loop insulin delivery. Participants/guardians signed consent/assent as appropriate. Participants were admitted twice to the research facility, 1--6 weeks apart, for 15--37 h, and consumed 1--4 meals accompanied by prandial insulin aspart. Basal aspart was delivered using closed-loop insulin delivery or conventional pump therapy. Venous blood samples were collected every 30--60 min to measure plasma insulin (Invitron, Monmouth, U.K.).

From 5,804 plasma insulin measurements, we estimated, using a two-compartment model, the time-to-peak plasma insulin concentration (*t*~max~ \[min\]), the metabolic clearance rate of insulin (MCR in mL/kg/min), and the background residual plasma insulin concentration (mU/L). Results are presented in [Table 1](#T1){ref-type="table"}. Sex differences in aspart kinetics were not observed. Aspart pharmacokinetics was weakly influenced by common clinical and anthropometric factors, because less than 20% of intersubject variability was explained by sex, BMI, total daily dose, A1C, and diabetes duration.
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We measured *t*~max~ comparable to literature reports ([@B1]) but observed higher inter- and intraindividual variability of *t*~max~ in T1D compared with healthy subjects, with intersubject coefficient of variation 33% vs. 20% and intrasubject coefficient of variation 27% vs. 15% (comparison against Heinemann et al. \[[@B2]\]). Nearly 40% of total variance was attributed to interoccasion variability, presumably due to variations in depth of cannula insertion, insulin site age, and local tissue perfusion. This considerable interoccasion variability suggests large intrapatient variability in postprandial insulin concentration even when prandial boluses are identical. A slower insulin absorption rate was associated with a higher BMI; the BMI *z* score did not alter this relationship in the young. Comparable findings using soluble insulin were reported in healthy subjects ([@B3]), but absorption of rapid-acting insulin in obese type 2 diabetes was not influenced by BMI ([@B4]).

MCR was highly reproducible. In the absence of a large bedtime bolus, overnight plasma insulin is dictated by basal pump settings. Pump settings are normally altered infrequently and, because MCR is reproducible, our data suggest that the overnight plasma insulin concentration in pump-treated patients is consistent between nights and unable to explain considerable night-to-night blood glucose variations often observed in T1D. The background insulin concentration decreased with diabetes duration. An ultrasensitive assay documented that C-peptide secretion persists over decades but decreases with disease duration ([@B5]). The background concentration observed in our data may reflect this residual secretion.

Our data lack standardization of insulin delivery, but we mitigated by the use of compartment modeling. Limitations are nonstandardized infusion sets, cannula placement, and age of cannula site likely increasing variability of absorption but representative of the standard clinical practice.

In conclusion, anthropometric and clinical factors are weakly associated with aspart pharmacokinetics. Sex does not affect aspart pharmacokinetics. The basal plasma insulin concentrations but not postprandial insulin levels are reproducible between occasions.
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